Bile Acids and Nonalcoholic Fatty Liver and Pancreas Disease: Going Together?

Abstract

Objective of the Review: to analyse changes in bile acids (BA) metabolism due to nonalcoholic fatty liver disease (NAFL), nonalcoholic fatty pancreas disease (NAFP); to assess the efficiency of ursodeoxycholic acid (UDCA) for their correction. Key Points. NAFL and NAFP have much in common, including BA synthesis imbalance and reduced farnesoid X receptor (FXR) expression. One possible therapy of NAFL and NAFP is BA synthesis correction and increase in FXR expression using FXR agonists. The article discusses clinical and experimental trials of the efficiency of selective FXR agonist — UDCA — in NAFL and NAFP. Conclusion. The multifactorial UDCA mechanism of action including anti-inflammatory, antioxidant, cytoprotective and antiapoptotic actions, can normalise carbohydrate, lipid metabolism and activate FXR; it can justify medicine inclusion into NAFL and NAFP therapeutic regimens. Keywords: nonalcoholic fatty liver disease, nonalcoholic fatty pancreas disease, ursodeoxycholic acid.

Study on synthesis of Ursodeoxycholic Acid by reduction of 7-Ketolithcholic Acid in Double Aprotic Solvents and Molecular simulations

“…With the in-depth study of ursodeoxycholic acid (3α, 7β-2-hydroxy-5β-cholanic acid, UDCA,) by scientists around the world, it has been discovered that ursodeoxycholic acid is not only in the treatment of hepatobiliary diseases such as cholesterol gallstones, diseases caused by cholestasis, but also various types of fatty liver [1][2][3][4] . Since there is no side effect, ursodeoxycholic acid is also widely used in kidney injury (Acute Kidney Injury) and Parkinson's Disease [5,6] . In 1902, this substance was rst discovered by Hammarsten in polar bear bile.…”